• Home
• About Institute
• Research & Development
• News & Info
• Contact Us
• Investors

Investors

Please find below, quick facts for investors. For additional information please contact investors@burzynskiresearch.com. For stock quotes and latest SEC fillings, please visit Yahoo! finance and look up ticker BZYR.OB

State of Incorporation: 

The Burzynski Research Institute, Inc. (BRI) was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name antineoplastons.

Shares and Shareholders:

Shares of Burzynski Research Institute are publicly traded with ticker symbol BZYR.OB. As of  As of May 20, 2008, there were approximately 2,027 holders of record of BRI’s Common Stock, as shown on the records of the Transfer Agent and Registrar of the Common Stock. Since many shares may be held by investors in nominee names, such as the name of their broker or their broker’s nominee, the number of record holders often bears little relationship to the number of beneficial owners of the Common Stock.

Orphan Drug Designation

Orphan Drug Designation has been granted to the Burzynski Research Institute, Inc., by the FDA’s Office of Orphan Drug Products Development, and is designed to encourage clinical development of products for use in rare diseases, or conditions usually defined as affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides an economic incentive that stimulates the development of new products in the oncology field, and allows for seven years of market exclusivity upon final FDA approval, as well as clinical study and R&D support, reduction in regulatory fees, and potential tax credit.

Dividends

Burzynski Research Institute, Inc. has never paid cash dividends on its Common Stock and the Board of Directors intends to retain all of its earnings, if any, to finance the development and expansion of its business. However, there can be no assurance that Burzynski Research Institute, Inc. can successfully expand its operations, or that such expansion will prove profitable. Future dividend policy will depend upon BRI’s earnings, capital requirements, financial condition and other factors considered relevant by BRI’s Board of Directors.

Board of Directors

Set forth below are the names, ages and positions of BRI’s directors and executive officers:

STANISLAW R. BURZYNSKI, M.D., PH.D., has been the President and Chairman of the Board of Directors of BRI since its inception in 1984. He also serves as BRI’s Secretary and Treasurer. Dr. Burzynski is a physician in private practice in Houston, Texas specializing in the treatment of cancer. Dr. Burzynski is the husband of Barbara Burzynski, M.D., who is a director of BRI.

Currently listed in Who’s Who In The World and a member in good standing with both the American and World Medical Associations, Dr. Burzynski is an internationally recognized physician and scientist who has pioneered the development and use of biologically active peptides in diagnosing, preventing, and treating cancer since 1967. In 1967, Dr. Burzynski graduated with distinction with an M.D. degree from the Medical Academy in Lublin, Poland, finishing first in his class of 250, and he subsequently earned his Ph.D. in Biochemistry.

From 1970 to 1977, he was a researcher and Assistant Professor at Baylor College of Medicine in Houston. At Baylor, Dr. Burzynski’s research was sponsored and partially funded by the National Cancer Institute. Also at Baylor, he authored and co-authored sixteen publications, including five concerning his research on peptides and their effect on human cancer. Four of these publications were also co-authored by other doctors associated with M.D. Anderson Hospital and Tumor Institute and Baylor College of Medicine. In May 1977, Dr. Burzynski received a Certificate of Appreciation from Baylor College of Medicine and in that same year founded BRI.

Dr. Burzynski is a member of the American Medical Association, American Association for Cancer Research, Harris County Medical Society, New York Academy of Sciences, Society for Neuroscience, Texas Medical Association, the Society of Sigma Xi, and the Society of Neuro-oncology. He is the author of over 300 scientific publications, presenter of scientific papers at major international conventions, and has been awarded 242 patents covering 44 countries for his Antineoplaston treatment and other inventions. Other groups are working in conjunction with him, including researchers at the University of Kurume Medical School in Japan.

BARBARA BURZYNSKI, M.D., a Director since 1984 and the wife of Dr. Burzynski, has been the Chairman of the Department of Pharmacy of the Burzynski Clinic since 1977. From January 1976 to July 1977, she was a Research Assistant in the Department of Pediatrics at Baylor College of Medicine. She was a physician at the Medical Academy, Lublin, Poland, from 1970 to 1975. Dr. Barbara Burzynski graduated with an M.D. in 1966 from the Medical Academy, Lublin, Poland, and has published nine publications on studies with ANP.

MICHAEL H. DRISCOLL, J.D., has been a Director of BRI since 1984. Mr. Driscoll was formerly a judge and served as the County Attorney of Harris County, Texas from 1981 until he retired in 1997.

CARLTON HAZLEWOOD, PH.D., has been a Director of BRI since 1997. He also serves as Chairman of the IRB, an independent review board for BRI’s clinical trials designated according to federal regulations. Dr. Hazlewood currently operates his own consulting company, Research Consultant’s International, and is president of Petroclean, L.L.C. In addition, Dr. Hazlewood was employed in various capacities by the Baylor College of Medicine from 1965 until December 31, 1997, where he was a professor of Molecular Biology and Biophysics. Dr. Hazlewood received his Ph.D. in Medical Physiology from the University of Tennessee. Dr. Hazlewood is a prolific writer on medical topics and has been recognized for his research with numerous awards, honors and research grants